LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

Search

Twist Bioscience Corp

Closed

SectorHealthcare

29.83 -6.81

Overview

Share price change

24h

Current

Min

29.63

Max

31.38

Key metrics

By Trading Economics

Income

-48M

-27M

Sales

3M

99M

EPS

-0.45

Profit margin

-27.41

Employees

979

EBITDA

-2.3M

-26M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+18.71% upside

Market Stats

By TradingEconomics

Market Cap

-75M

1.8B

Previous open

36.64

Previous close

29.83

News Sentiment

By Acuity

50%

50%

166 / 374 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Twist Bioscience Corp Chart

Past performance is not a reliable indicator of future results.

Related News

1 Dec 2025, 21:16 UTC

Acquisitions, Mergers, Takeovers

Marsh McLennan Agency Acquires Three Hawaii-Based Insurance Brokerages

1 Dec 2025, 18:51 UTC

Major Market Movers

Shopify Stock Falls on Cyber Monday System Outages

1 Dec 2025, 23:47 UTC

Market Talk

Nikkei May Rise on Bargain Hunting -- Market Talk

1 Dec 2025, 23:27 UTC

Acquisitions, Mergers, Takeovers

Genting Bhd. Stake in Genting Malaysia Now at 73.13% Vs. 49.36% Ahead of Take Private Offer Made in October

1 Dec 2025, 23:26 UTC

Acquisitions, Mergers, Takeovers

Genting Bhd.: Offer to Take Genting Malaysia Private Closed on Dec.1

1 Dec 2025, 23:25 UTC

Acquisitions, Mergers, Takeovers

Bitcoin Rout Picks Up Steam as Investors Fret Over a New 'Crypto Winter' -- WSJ

1 Dec 2025, 21:52 UTC

Acquisitions, Mergers, Takeovers

Wood Partners Announces Itochu Corp. Purchase of 19.5% of Wood Partners

1 Dec 2025, 21:42 UTC

Acquisitions, Mergers, Takeovers

Goldman's Latest Acquisition Is a $2 Billion Bet on Active ETFs -- Barrons.com

1 Dec 2025, 21:41 UTC

Market Talk

Canada's GDP Revisions Mean Lower Debt-to-GDP Ratio, Better Productivity -- Market Talk

1 Dec 2025, 21:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 Dec 2025, 21:41 UTC

Market Talk

Canada's GDP Revisions Mean Lower Debt-to-GDP Ratio, Better Productivity -- Market Talk

1 Dec 2025, 21:17 UTC

Acquisitions, Mergers, Takeovers

Commercial Metals Expects to Close Foley Products Deal by End of 2025 >CMC

1 Dec 2025, 21:17 UTC

Acquisitions, Mergers, Takeovers

Commercial Metals Completes Acquisition of Concrete Pipe & Precast for $675M Cash >CMC

1 Dec 2025, 21:15 UTC

Acquisitions, Mergers, Takeovers

Commercial Metals Completes Acquisition Of Concrete Pipe & Precast, LLC >CMC

1 Dec 2025, 20:15 UTC

Market Talk

Natural Gas Turns Positive Amid Mixed Weather Trends -- Market Talk

1 Dec 2025, 20:00 UTC

Acquisitions, Mergers, Takeovers

Marsh McLennan Agency Acquires Three Hawai'i-based Insurance Brokerages >MMC

1 Dec 2025, 18:54 UTC

Market Talk

Silver Hits New Record As Momentum Continues -- Market Talk

1 Dec 2025, 18:46 UTC

Market Talk

Luxury Seen With Accelerating Growth Next Year -- Market Talk

1 Dec 2025, 16:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 Dec 2025, 16:41 UTC

Market Talk

Rapid Wage Growth in Canada to Keep BOC Sidelined -- Market Talk

1 Dec 2025, 16:20 UTC

Market Talk

Yen Could Strengthen Further Against Dollar on Rate-Hike Prospects -- Market Talk

1 Dec 2025, 16:00 UTC

Earnings

Strategy Helped Solve Its Bitcoin-Preferred Problem. Here's How. -- Barrons.com

1 Dec 2025, 15:51 UTC

Acquisitions, Mergers, Takeovers

Goldman Makes a $2 Billion Bet on 'Boomer Candy' -- WSJ

1 Dec 2025, 15:47 UTC

Market Talk

Global Equities Roundup: Market Talk

1 Dec 2025, 15:47 UTC

Market Talk

Airbus Guidance Is at Risk -- Market Talk

1 Dec 2025, 15:46 UTC

Acquisitions, Mergers, Takeovers

Synopsys Gets a New Investor. What to Know About Nvidia's Stake. -- Barrons.com

1 Dec 2025, 15:33 UTC

Market Talk

Airbus Selloff May Be Overdone -- Market Talk

1 Dec 2025, 15:26 UTC

Market Talk

Warming Forecast Pressures Natural Gas -- Market Talk

1 Dec 2025, 15:23 UTC

Market Talk

Geopolitical Turmoil Supports Crude Oil -- Market Talk

1 Dec 2025, 14:59 UTC

Acquisitions, Mergers, Takeovers

Goldman's Latest Acquisition Is a $2 Billion Bet on Active ETFs -- Barrons.com

Peer Comparison

Price change

Twist Bioscience Corp Forecast

Price Target

By TipRanks

18.71% upside

12 Months Forecast

Average 38 USD  18.71%

High 42 USD

Low 32 USD

Based on 5 Wall Street analysts offering 12 month price targets forTwist Bioscience Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

31.56 / 38.6884Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

166 / 374 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat